2016
DOI: 10.18632/aging.101146
View full text | Cite
|
Sign up to set email alerts
|

Abstract: One important process in liver cancer growth and progression is angiogenesis. Vascular endothelial growth factor (VEGF) has the significant role in liver cancer angiogenesis. sFlt1 (soluble Fms-like tyrosine kinase-1) is the promising inhibitor of VEGF and can be used as the new method of inhibiting angiogenesis. MSCs (Mesenchymal stem cells) can infiltrate into tumor tissue and function as the efficient transgene delivery mediator. Here, we engineered murine MSCs to express sFlt1 and examined the anti-tumor e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 34 publications
(33 reference statements)
0
3
0
Order By: Relevance
“…Additionally, sFlt1 is thought to be a natural antagonist of VEGF . Recent studies have found that sFlt1 has an antitumor effect on several cancer cells ( 48 50 ). Enhanced sFlt1 expression in the serum of breast cancer patients inhibits circulating tumor cells entering the peripheral blood, which may contribute to favorable outcomes ( 51 ).…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, sFlt1 is thought to be a natural antagonist of VEGF . Recent studies have found that sFlt1 has an antitumor effect on several cancer cells ( 48 50 ). Enhanced sFlt1 expression in the serum of breast cancer patients inhibits circulating tumor cells entering the peripheral blood, which may contribute to favorable outcomes ( 51 ).…”
Section: Discussionmentioning
confidence: 99%
“…Several studies have shown that engineered‐MSCs could migrate to the tumor and metastatic sites and deliver the anticancer agents including IFN‐α, IFN‐ß, CX3CL1, IL‐2, IL‐12, NK4, sFIT‐1, and suicide gene 22,29,37,38 . Recently, various investigations have focused on TRAIL as one of the most promising anticancer factors.…”
Section: Discussionmentioning
confidence: 99%
“…Importantly, the effectiveness and safety of this combination therapy are verified through in vivo experiments. 31,32 MiR-199a-3p, the third most highly expressed miRNA in the normal liver, is down-regulated in almost all HCC cells and associated with poor prognosis. And mTOR has been identified as the direct target of miR-199a-3p.…”
Section: Mscs and Adriamycinmentioning
confidence: 99%